if that patient has a bicuspid valve? How is your decision making going to

be? That's a tricky question because there are a lot of elements that we have to take into consideration, right? I think one thing is for sure that from most randomized trials that you have just mentioned, patients with bicuspid valves were excluded.

So all the data that we have, long-term data, relates to patients with tricuspid aortic valve.

On the other hand, I think there is no bicuspid valve in general, you know, I think type one, especially in Europe, and I think that's comparable in all our countries.

It's more or less the same.

It's very, very rare.

If it's a type 1 bicuspid valve, which is normally the case, it depends on the details.

Do you think the field moving forward Do you think that the field is moving in that direction, that we go even younger? Or should we first solve some of the issues we have just spoken about before moving even below 70?